Clinical trial
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
NCT02589847 · Rebiotix Inc., Industry · Completed
Key facts
| NCT number | NCT02589847 |
|---|---|
| Title | Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection |
| Official title | An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection |
| Lead sponsor | Rebiotix Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Clostridium Difficile Infection |
| Intervention type | Biological, Drug |
| Interventions | RBX2660, Standard of Care Antibiotics |
| Enrollment | 272 |
| Start date | Oct 1, 2015 |
| Primary completion | Jun 1, 2017 |
| Completion | Mar 1, 2019 |
| First posted | Oct 28, 2015 |
| Last update posted | Mar 26, 2021 |
| Countries | Canada, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: